Oxygen mapping in pancreatic tumors could reveal hidden clues to aggressive cancer

NCT ID NCT01248637

Completed Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study investigates low-oxygen (hypoxic) areas within pancreatic tumors by giving patients a special marker before surgery. The marker highlights oxygen-deprived regions in the removed tumor tissue. Researchers will then analyze how these hypoxic zones relate to patient survival and other biological markers. The goal is to better understand pancreatic cancer behavior and potentially identify new targets for treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pimonidazole hydrochloride
What this could lead to: If successful, this could help doctors predict which pancreatic cancers are more aggressive and guide personalized treatment strategies.
What could go wrong: This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypoxia malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Show contact details

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.